245 related articles for article (PubMed ID: 32393791)
1. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
2. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells.
Cusimano A; Puleio R; D'Alessandro N; Loria GR; McCubrey JA; Montalto G; Cervello M
Oncotarget; 2015 Jan; 6(3):1707-22. PubMed ID: 25596737
[TBL] [Abstract][Full Text] [Related]
4. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth
Ye X; Ruan JW; Huang H; Huang WP; Zhang Y; Zhang F
Aging (Albany NY); 2020 May; 12(10):9489-9499. PubMed ID: 32421688
[TBL] [Abstract][Full Text] [Related]
5. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
6. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Wu WS; Chien CC; Chen YC; Chiu WT
PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
9. GDC-0349 inhibits non-small cell lung cancer cell growth.
Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G
Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352
[TBL] [Abstract][Full Text] [Related]
10. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway.
Chen W; Zhao S; Yu W; Rao T; Ruan Y; Zhu S; Xia Y; Song H; Cheng F
J Cell Mol Med; 2021 Nov; 25(22):10684-10697. PubMed ID: 34687144
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AKT enhances the anti-cancer effects of Artemisinin in clear cell renal cell carcinoma.
Yu C; Sun P; Zhou Y; Shen B; Zhou M; Wu L; Kong M
Biomed Pharmacother; 2019 Oct; 118():109383. PubMed ID: 31545251
[TBL] [Abstract][Full Text] [Related]
12. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan-Induced Cytotoxicity via G
Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
16. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
17. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
18. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
19. Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.
Lin TC; Liu YP; Chan YC; Su CY; Lin YF; Hsu SL; Yang CS; Hsiao M
J Pathol; 2015 Sep; 237(1):50-61. PubMed ID: 25925728
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
